AtriCure (NASDAQ:ATRC) Earns Hold Rating from Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of AtriCure (NASDAQ:ATRC – Get Rating) in a research report issued on Thursday. The firm set a “hold” rating on the medical device company’s stock.

ATRC has been the topic of several other reports. Stifel Nicolaus decreased their target price on shares of AtriCure from $55.00 to $48.00 and set a “buy” rating on the stock in a research note on Wednesday, February 22nd. Needham & Company LLC reiterated a “buy” rating and issued a $58.00 price target on shares of AtriCure in a report on Wednesday, February 22nd. Canaccord Genuity Group cut their price target on shares of AtriCure from $81.00 to $74.00 and set a “buy” rating on the stock in a report on Wednesday, February 22nd. Finally, BTIG Research cut their price target on shares of AtriCure from $65.00 to $55.00 and set a “buy” rating on the stock in a report on Wednesday, February 22nd. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $59.17.

AtriCure Stock Down 0.4 %

Shares of NASDAQ ATRC opened at $39.20 on Thursday. The company has a quick ratio of 2.90, a current ratio of 3.69 and a debt-to-equity ratio of 0.14. AtriCure has a 52 week low of $32.51 and a 52 week high of $68.58. The firm’s fifty day moving average is $41.50 and its 200 day moving average is $42.06. The company has a market cap of $1.83 billion, a price-to-earnings ratio of -38.81 and a beta of 1.31.

AtriCure (NASDAQ:ATRC – Get Rating) last issued its earnings results on Tuesday, February 21st. The medical device company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.09. AtriCure had a negative net margin of 14.06% and a negative return on equity of 10.18%. The company had revenue of $88.00 million for the quarter, compared to the consensus estimate of $87.90 million. During the same period in the previous year, the firm earned ($0.30) earnings per share. The firm’s revenue for the quarter was up 20.2% on a year-over-year basis. On average, equities research analysts expect that AtriCure will post -1.07 earnings per share for the current year.

Institutional Trading of AtriCure

A number of hedge funds have recently modified their holdings of the business. Advisors Capital Management LLC boosted its holdings in shares of AtriCure by 0.6% during the 4th quarter. Advisors Capital Management LLC now owns 45,679 shares of the medical device company’s stock valued at $2,027,000 after buying an additional 283 shares in the last quarter. Rockefeller Capital Management L.P. boosted its holdings in shares of AtriCure by 15.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 2,444 shares of the medical device company’s stock valued at $108,000 after buying an additional 319 shares in the last quarter. Mariner LLC boosted its holdings in shares of AtriCure by 6.3% during the 4th quarter. Mariner LLC now owns 5,715 shares of the medical device company’s stock valued at $254,000 after buying an additional 337 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in shares of AtriCure by 3.2% during the 4th quarter. Principal Financial Group Inc. now owns 11,640 shares of the medical device company’s stock valued at $517,000 after buying an additional 359 shares in the last quarter. Finally, Lazard Asset Management LLC boosted its holdings in shares of AtriCure by 29.7% during the 3rd quarter. Lazard Asset Management LLC now owns 1,818 shares of the medical device company’s stock valued at $71,000 after buying an additional 416 shares in the last quarter. Institutional investors own 95.27% of the company’s stock.

AtriCure Company Profile

(Get Rating)

AtriCure, Inc engages in the development, manufacture, and sale of surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration.